Lapatinib
About
Therapy type: Targeted therapy
Therapy strategy: HER2 inhibition
Mappings
NCI Thesaurus: Lapatinib (ncit:C26653)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Capecitabine, Lapatinib | |
| Sensitivity (+) | ER positive, HER2-positive | Invasive Breast Carcinoma | Lapatinib, Letrozole | |
| Sensitivity (+) | HER2-positive, PR positive | Invasive Breast Carcinoma | Lapatinib, Letrozole | |
| Sensitivity (+) | ER positive, HER2-positive, PR positive | Invasive Breast Carcinoma | Lapatinib, Letrozole | |
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Capecitabine, Lapatinib | |
| Sensitivity (+) | ERBB2 amplification | Invasive Breast Carcinoma | Capecitabine, Lapatinib | |
| Sensitivity (+) | ER positive, HER2-positive, PR negative | Invasive Breast Carcinoma | Lapatinib, Trastuzumab | |
| Sensitivity (+) | ER positive, ERBB2 amplification, PR negative | Invasive Breast Carcinoma | Lapatinib, Trastuzumab | |
| Sensitivity (+) | ER positive, HER2-positive, PR positive | Invasive Breast Carcinoma | Lapatinib, Letrozole | |
| Sensitivity (+) | ER positive, ERBB2 amplification, PR positive | Invasive Breast Carcinoma | Lapatinib, Letrozole |